Drug Trial Radar · NCT04377750
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation
Last checked: Nov 19, 2026Latest source record: May 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
500
Planned (sponsor's estimate)
Start
Apr 8, 2020
Primary completion
Apr 29, 2020
Study completion May 8, 2021
Sponsor
- Lead sponsor
- Hadassah Medical OrganizationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sheba Medical Center; Wolfson Medical Center
- First posted
- May 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Title: The use of Tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. This is a study designed to assess the therapeutic value of intravenous tocilizumab administered as single 8mg/Kg dose in patients affected by SARS-CoV2 infection with a pulmonary manifestation causing hypoxia. Aim of the study is to test the hypothesis that anti-IL6 treatment can be effective in reducing the virus-induced cytokine storm, blocking deterioration of lung function or even promoting a rapid improvement of clinical conditions, preventing tracheal intubation and/or death. This drug will be administered to those patients entering the ICU with severe acute respiratory failure COVID-19 disease. The endpoints are death and duration of hospitalization. The patients will be assessed with surrogate markers determining the level of the cytokine storm.
Conditions
- Covid19 Pneumonia
Interventions
TocilizumabDrug
The placebo treatment arm will include 100 ml of normal saline administered along 60 min
Primary outcomes
What the sponsor says the trial is designed to measure.
- SurvivalTime frame: One-month
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Barzilai Medical Center
Ashkelon, Israel · Recruiting
Wolfson Medical Center
Holon, Israel · Recruiting
Sheba Medical Center
Ramat Gan, Israel · Recruiting
Hadassah Medical Orginisation
Jerusalem, Please Select:, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.